World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
About Valneva SEValneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
90 articles with Valneva SE
Valneva SE, a specialty vaccine company, reported consolidated financial results for the first half of the year, ended June 30, 2022.
Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
ValnevaSE, a specialty vaccine company, announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held yesterday in Paris.
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.
Pfizer inked an Equity Subscription Agreement with France-based Valneva. They also updated their Collaboration and License deal for a Lyme disease vaccine that was announced in April.
Valneva SE, a specialty vaccine company, announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.
Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th Northern European Conference on Travel Medicine in Rotterdam.
ValnevaSE, a specialty vaccine company, announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE, a specialty vaccine company, announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Saint Herblain, May19, 2022 – Valneva SE, a specialty vaccine company, confirmed that the European Medicines Agency has accepted the filing of a marketing authorization application for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.
Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement
ValnevaSE announced that it has received a notice from the European Commission of intent to terminate the advance purchase agreement for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001.
Valneva SE, a specialty vaccine company, reported its first quarter financial results ending March 31, 2022 and provided corporate updates.
A roundup of last week's top clinical trial updates and news.
Pfizer and its partner, Valneva, have announced positive Phase II data from its trial of vaccine candidate VLA15 in a pediatric population. VLA15 is intended to prevent Lyme Disease (LD).
Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
Valneva SE, a specialty vaccine company, announced an agreement to increase the principal amount of its existing $60 million debt financing agreement with funds managed by leading US-based healthcare investment firms Deerfield Management Company and OrbiMed.
Saint-Herblain and New York, April 26, 2022 – Valneva SE, a specialty vaccine company, and Pfizer Inc. reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine
Valneva SE announced that the Medicines and Healthcare products Regulatory Agency of the United Kingdom has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.
Saint-Herblain, March24, 2022 – Valneva SE, a specialty vaccine company, reported its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.